Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S. construct ... www.cel-sci.com Keywords: AIDS, Acquired Immunodeficiency Syndrome, Adverse Drug Reaction, Arthritis, Biotechnology, Cancer Vaccines, Cytokines, Genetics, H1N1 Virus, ...
2009 NOV 23 ... to trigger receptor-mediated transport across the BBB, and TNF alpha, to sequester this cytotoxic cytokine. COS cells were dual transfected with the heavy chain (HC) and light chain ... Molecular Pharmaceutics (Tumor Necrosis Factor Receptor-IgG Fusion Protein for Targeted Drug Delivery across the Human Blood-Brain Barrier. Molecular Pharmaceutics, ...
2009 NOV 23 ... factor (rhG-CSF) is widely used as treatment for granulocytopaenia during cytotoxic chemotherapy; however, optimal scheduling of this pharmaceutical is unknown. ... equations model of pharmacokinetics was constructed on the basis of known mechanisms of drug distribution and degradation. Predictions of the model fit well with all experimental ...
2009 NOV 23 ... please sign up today free at www.minamargroup.com/updates Keywords: Cancer, Cytotoxic Drug, Oncology, Therapy, Treatment, Hard to Treat Diseases. This article was ...
2009 NOV 23 ... or encapsulated in liposomes. XMT-1001 is a conjugate of the broad-spectrum cytotoxic camptothecin (CPT) that employs Mersana's Fleximer=AE platform. XMT-1001 is currently ... lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for ...
2009 NOV 23 ... treatments for Glioblastoma multi-forme (GBM) involve surgery, radiotherapy, and cytotoxic chemotherapy; however, these treatments are not effective and there is an urgent need ... is an urgent need for better treatments. We investigated GBM cell killing by a novel drug combination involving DT-EGF, an Epidermal Growth Factor Receptor-targeted bacterial ...
2009 NOV 23 ... vomiting, and alopecia. Hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy. It is more frequently associated with 5-FU, capecitabine, and cytarabine. ... to significant morbidity. Hand-foot syndrome seems to be dose dependent, and both peak drug concentration and total cumulative dose determine its occurrence," wrote A. Shahrokni ...
2009 NOV 23 ... measuring calcium flux and the dynamics of target cell killing induced by conjugated cytotoxic T-lymphocytes. We found large variations among individual cells in the overall amplitude ... new data in life sciences. "Advances in molecular cell biology, medical research, and drug development are driving a growing need for technologies that enable imaging the dynamics ...
2009 NOV 23 ... bulky residual tumor that persisted despite radiation therapy (RT) and two cycles of cytotoxic chemotherapy. Vorinostat and retinoic acid were chosen as an alternative to cytotoxic ... States, Life Sciences, Vorinostat, Drugs, Therapy, Treatment, Radiation Therapy, Drug Therapy, Chemotherapy, Oncology, Retinoic Acid, Neuro-Oncology, Neurooncology, ...
2009 NOV 23 ... which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in ... Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company Insight and analysis of market potential including ...
2009 NOV 23 ... zwitterionic vesicles or even detergents. Furthermore, no evidence of antibacterial or cytotoxic activity from soluble aDrs could be obtained. The peptide has an inherent propensity to ... Antimicrobial, Antimicrobials, Bioengineering, Biotechnology, Cytotoxic Activity, Drug Development, Peptide Self-assembly, Proteomics, Therapy, Treatment, Johannes Kepler ...
2009 NOV 23 ... "Targeted treatment has substantially changed the field of oncology. Compared with cytotoxic chemotherapy, many novel targeted therapies are administered over long periods of time, ... Life Sciences, Solid Cancers, Solid Carcinomas, Oncology, Pharmaceuticals, Drug Development, Therapy, Treatment, Drug Therapy, Chemotherapy, Clinical Oncology, Radboud ...
2009 NOV 23 ... control mice but the tumor-infiltrating effector T cells in AdCD40L-treated mice were cytotoxic (CD107a+) in contrast to those in control-treated tumors. Furthermore, AdCD40L gene ... Apoptosis, Biotechnology, Bladder Cancer, Bladder Carcinoma, Cancer Gene Therapy, Drug Development, Genetics, Genomics, Immunotherapy, Oncology, Pharmaceuticals, Treatment, ...
2009 NOV 23 ... purification, and characterization of Affitoxin-a novel class of HER2-specific cytotoxic molecules combining HER2-specific Affibody molecule as a targeting moiety and PE38KDEL, ... State:MD, Country:United States, Anticancer Therapy, Breast Cancer, Breast Carcinoma, Drug Development, Immunotherapy, Oncology, Pharmaceuticals, Therapy, Treatment, Women's ...
2009 NOV 23 ... material. A material that has a reduced systemic toxicity will allow higher doses of cytotoxic drugs to be delivered to the tumor with reduced side effects. Preliminary experiments ... According to recent research from the United States, "Magnetic nanoparticle drug carriers continue to attract considerable interest for drug targeting in the treatment ...
2009 NOV 23 ... length. After NIR triggered drug release, the released Pt compounds were observed to be cytotoxic, while remaining nanoparticles did not exhibit any cytotoxicity," wrote M.C. Tan and ...
2009 NOV 23 ... Immunology Immunotherapy (Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. Cancer Immunology Immunotherapy, ... USA. Keywords: City:Chongqing, Country:People's Republic of China, Cancer, Drug Development, Immunology, Immunotherapy, Oncology, Pharmaceuticals, Therapy, Treatment, ...
2009 NOV 23 ... of in-stent restenosis and late stent thrombosis is intuitively favored over the use of cytotoxic or cytostatic drugs released from a drug-eluting stent (DES). Promoting accelerated ...
2009 NOV 23 ... neuroblastoma (NB), a tumor that relapses at high rates following high-dose conventional cytotoxic therapy and autologous bone marrow cell (BMC) reconstitution. This study presents a ... USA. Keywords: Country:Israel, Bone Marrow, Cancer, Cytotoxic Activity, Drug Development, Hematology, Immunology, Immunotherapy, Neuroblastoma, Oncology, Therapy, ...
2009 NOV 16 ... exhibit antibacterial activity against any of the bacterial strains tested and are not cytotoxic against HeLa cells," wrote T.J. Opperman and colleagues, Microbiotix, Inc. ... Worcester, Antimicrobials, Biotechnology Business, Biotechnology Company, Chemotherapy, Drug Therapy, Microbiotix Inc., Staphylococcus Infections, Microbiotix, Inc. ...
